Zydus Cadila to market four products in the US after USFDA approval
16 May 2008
Mumbai: Ahmedabad-based pharma company, Zydus Cadila has received approval from the United States Food and Drug Agency (USFDA) to market the anti-cholestrol pravastatin sodium in tablet form in the US.
The Indian pharma major has also received a tentative approval to market escitalopram oxalate Tablets, 5,10 and 20 mg, Losartan potassium and hydrochlorthiazide tablets 50mg / 12.5 mg and 100mg / 25mg and anastrazole tablets 1mg, used for the treatment of depression and anxiety.
According to a statement, Cadila will make 10mg, 20mg, 40mg, 80mg of pravastatin sodium tablets in the US.
The pravastatin sodium tablets, a lipid lowering compound, which reduce cholesterol biosynthesis, is used in to prevent coronary events in patients with high levels of cholesterol in the blood.
The market size of pravastatin sodium tablets, which falls in the cardiovascular segment, was estimated at $1.9 billion in 2007, while that of escitalopram oxalate tablets, an anti-depressant, was estimated at $3 billion.
The sale of anti-hypertensive Losartam Potassium and Hydrochlorthiazide tablets stood at $785 million, while Anastrazole tablets had a market of $813 million dollar, during the same period.
